A remark by Stuart Hepburn, Life Technologies Inc.'s directorof corporate development, in the Jan. 14 issue of BioWorldconcerning Becton DickinsonUs license of crossovercontamination technology from LTI may have erroneouslyimplied that Becton Dickinson uses or is contemplating usingpolymerase chain reaction (PCR) in its DNA amplification-basedmolecular biology diagnostics.

(c) 1997 American Health Consultants. All rights reserved.